Background
Esophageal cancer, an aggressive upper gastrointestinal malignancy, generally presents as a locally advanced disease and requires a multimodal concept. Despite improvements in its detection and management, the prognosis in patients with esophageal cancer remains poor, with a 5-year survival of 15–34% [
1,
2]. Most patients who undergo curative treatment for esophageal cancer will eventually relapse and die as a result of their disease. Neoadjuvant chemoradiotherapy (CCRT) can increase the chance of R0 resection, and responders will have a survival benefit [
3]. Patient selection is important to guide multidisciplinary therapy. The identification of potential molecular markers to predict response to CCRT and recurrence is important for the effective management and prognosis of esophageal cancer.
Proinflammatory cytokine may contribute to tumor progression by stimulating angiogenesis, invasion and metastasis [
4,
5] IL-6 is a pleiotropic cytokine that is capable of modulating diverse cell functions such as inflammatory reactions, and is a major activator of the JAK/STAT3 and PI3K/AKT signaling pathways [
6]. IL-6 signaling has been implicated in the regulation of tumor growth and metastatic spread in different cancers [
7‐
9]. Moreover, increased IL-6 serum levels were reported to be associated with metastasis and poor prognosis in prostate, ovarian and gastrointestinal cancers [
10‐
12]. Although evidence suggests that IL-6 is a critical factor in a variety of malignancies [
11,
13,
14], how IL-6 modulates the biological activities of esophageal carcinoma cells and how it is associated with the prognosis of esophageal cancer remains unclear. There are two distinct histological types of esophageal cancer: squamous cell carcinoma (SCC) and adenocarcinoma. There are marked differences between these carcinomas in incidence, natural history and treatment outcomes [
15]. The majority of esophageal SCC cases occur in Asia, with the predominant type in Taiwan being SCC [
16]. We therefore investigated the role of IL-6 in esophageal SCC
in vitro and
in vivo, and examined the correlation between IL-6 levels and clinical outcomes in esophageal cancer patients.
Materials and methods
Patient characteristics
The Institutional Review Board of Chang Gung Memorial Hospital approved the present study (Permit Number: 96-1693B). The written consents were signed by the patients for their specimen and information to be stored in the hospital and used for research. Patients who did not comply with the treatment regimen and those who received surgery alone for early-stage esophageal cancer were excluded from the study. A total of 173 patients with esophageal SCC who completed curative treatment were enrolled in the study. The curative treatment for esophageal cancer included neoadjuvant CCRT combined with surgery or definitive CCRT according to the guidelines proposed by oncology team at our hospital. On completion of neoadjuvant CCRT, patients underwent a repeat CT scan and endoscopic examination to determine the response to treatment. If the tumor was considered resectable, patients underwent surgery for the residual tumor. Pathologic complete response (CR) was defined as absence of residual invasive tumor in the surgical specimen in patients undergoing surgical intervention. For patients who refused surgery or in whom it was contraindicated, a second round of CCRT was administered, comprising two courses of chemotherapy and radiotherapy of a total of 60–63 Gy. Specimens collected from the 173 patients at diagnosis were subjected to immunochemical analysis. The main end points were overall survival (OS), disease-free survival (DFS) and response to neoadjuvant therapy. Survival probability was analyzed statistically using the Kaplan–Meier method. The significance of between-group differences was assessed using the log-rank test. Multivariate analyses were performed using a Cox regression model for survival.
Immunohistochemical staining (IHC)
Formalin-fixed, paraffin-embedded tissues from 173 patients with esophageal cancer were subjected to IHC staining. Dissected esophageal cancer specimens from 20 of these patients were converted into tissue microarray (TMA) blocks using an AutoTiss 1000 arrayer (Ever BioTechnology, Canada). The TMA block contained esophageal SCCs and the adjacent non-malignant epithelium. The quality of the TMA slides was confirmed by the pathologist using hematoxylin- and eosin-stained slides. The IHC data for the specimens were assessed using the semi-quantitative immunoreactive score (IRS). The criterion for positive staining was an IRS score of ≥2. The details were described in Additional file
1: Supplementary methods.
Cell culture and reagents
The human esophageal cancer cell line CE81T, derived from a well-differentiated esophageal SCC, was obtained from the Bioresource Collection and Research Center (BCRC),and cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum. The IL-6-neutralizing antibody, STAT3 siRNA and the JAK inhibitor AG490 were purchased from R&D Systems (Minneapolis, MN) and Sigma (St. Louis, MO), respectively. The IL-6-GFP silencing vector (human IL6 shRNA constructs in retroviral GFP vector) and GFP-control vector (Non-effective scrambled shRNA cassette in retroviral GFP vector) were purchased from Origene Technologies, Inc. (Rockville, MD). Transfection in CE81T was carried out by Lipofectamine™ 2000 (Invitrogen) according to the manufacturer’s instructions. Stable cancer cells were generated by transfecting CE81T cells with either the IL-6 silencing vectors or control vectors, followed by selection with puromycin for 4 weeks.
Cell growth
To measure cell growth, 1×104 cells per well were plated into 6-well dishes. At the indicated time-points, cells were trypsinized, collected and surviving cells counted using Trypan blue exclusion, from which the survival curves for CE81T transfectants ( wild type, with control vectors, and with IL-6 silencing vectors) were established.
Immunoblotting
To determine the
in vitro effects of STAT3 siRNA, proteins were extracted from cells transfected with STAT3 siRNA for 72 h. To determine the
in vitro effects of the JAK inhibitor and the anti-IL-6 antibody, proteins were extracted from cells incubated in the presence of 50 μM AG490 or 5 μg/ml IL-6 neutralizing antibodies for 24 h. The details were described in Additional file
1: Supplementary methods.
Immunofluorescence staining (IF) and Statistical analysis
The details were described in Additional file
1: Supplementary methods.
Enzyme-linked immunosorbent assay (ELISA) analysis of IL-6 level
We examined the serum level of IL-6 from 71 patients among subjects enrolled with esophageal cancer in the present study. For serum specimen, five milliliters of peripheral blood were drawn from each patient. Moreover, IL-6 levels in cellular supertnant and murine serum were tested. Levels of IL-6 in samples were analyzed using an IL-6 Quantikine ELISA Kit (R&D system). The details were described in Additional file
1: Supplementary methods.
Tumor xenografts
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals as promulgated by the Institutes of Laboratory Animal Resources, National Research Council, U.S.A. The protocol was approved by the Committee on the Ethics of Animal Experiments of Chang Gung Memorial Hospital (Permit Number: 2012080903). Eight-week-old male athymic nude mice were used and all animal experiments conformed to the protocols approved by the experimental animal committee of our hospital. CE81T cancer cell transfectants (1 × 10
6 per implantation, five animals per group) were subcutaneously implanted in the dorsal gluteal region. To determine
in vivo radiosensitivity, local irradiation (15 Gy) was performed when the tumor volume reached 500 mm
3. Radiosensitivity was indicated by a growth delay (
i.
e., the time required for the tumor to recover its previous volume after irradiation). Duplicate experiments were performed for growth delay analyses. The details were described in Additional file
1: Supplementary methods.
Discussion
Understanding the molecular mechanisms underlying aggressive tumor growth in esophageal SCC is pivotal to identifying novel targets for pharmacological intervention. Furthermore, clinical data [
2,
3,
23] suggest the need for markers that predict responses to neoadjuvant CCRT and help to identify patients at high risk of tumor recurrence and distant metastasis. However, no suitable markers have been identified to date. The inflammatory cytokine IL-6 contributes to the growth and progression of various malignancies, such as HNSCC, prostate cancer and gastrointestinal cancer, and acts as an autocrine growth factor and an anti-apoptotic factor for various stimuli, including anticancer agents [
11,
24‐
27]. Moreover, the IL-6/STAT3 pathway is important for the development of inflammation-associated intestinal tumorigenesis. Similar to other series [
11,
28], we found that IL-6 and IL-6R were detected in both esophageal cancer specimens and esophageal carcinoma cell lines. IL-6 expression was higher in esophageal cancer specimens compared with non-malignant tissues. Furthermore, positive staining for IL-6 was associated with higher tumor stage, higher rates of tumor recurrence and distant metastasis. To further investigate whether IL-6 was responsible for aggressive tumor growth in esophageal SCC, we suppressed IL-6 in esophageal cancer cells using a silencing vector. Data obtained from cell and xenograft tumor growth experiments revealed that inhibiting IL-6 resulted in slower tumor growth and reduced invasiveness. The transformation of an epithelial cell into a mesenchymal cell appears to be functionally relevant to the invasive characteristics of epithelial tumors, including esophageal cancer [
19,
29,
30]. At the molecular marker level, EMT is characterized by the loss of E-cadherin and increased expression of invasion-related factors [
31]. In cell experiments, the IL-6 silencing vector induced both an increase in E-cadherin levels in esophageal cancer cells, and decreases in MMP-9 levels. Constitutive activation of STAT3 signaling has been reported to contribute to oncogenesis by promoting proliferation and EMT, and IL-6 is a major activator of JAK/STAT3 signaling [
8,
32‐
34]. Therefore, we examined the links between STAT3 activation, IL-6 and EMT. When blocking STAT3 activation by STAT3 siRNA or JAK inhibitor, the decreases in EMT-related protein levels were comparable to those induced by IL-6 silencing vector. Furthermore, IHC data obtained from clinical samples demonstrated that IL-6 expression was significantly correlated with p-STAT3 staining. Therefore, it is likely that STAT3 activation plays a role in transmitting IL-6 signals to downstream targets that regulate EMT and invasiveness.
In the present study, IL-6 silencing vectors significantly decreased IL-6 levels seen in the supernatant of cell culture medium and the serum of mice bearing tumors. Moreover, in the clinic, IL-6 serum levels seem to be elevated in a subgroup of patients with local-regional failure or distant metastasis. We assume that circulating IL-6 plays an important role to stimulate tumor growth
in vivo, besides direct action on malignant cells. Angiogenesis is one of the mechanisms that promote tumor progression, and CD31-mediated endothelial cell-cell interactions are involved in angiogenesis. Moreover, STAT3 activation has been reported to modulate the expression of genes that mediate angiogenesis;
e.
g., VEGF [
35]. Accordingly, the links between IL-6, angiogenesis, and promotion of cancer in tumor-bearing mice were further investigated using a xenograft tumor model. Our data from animal experiments demonstrated that IL-6 level positively linked with angiogenesis in addition to EMT. These findings indicated that the promotion of EMT changes and angiogenesis mediate the aggressive tumor growth noted in IL-6 expressing esophageal cancer, at least in part.
Radiotherapy is a well-established therapeutic modality in oncology. It provides survival benefits in several cancer types, including esophageal cancer. For esophageal SCC, treatment response is an independent prognostic factor. We demonstrated that positive IL-6 staining was significantly associated with a lower response rate after treatment in patients with esophageal SCC. As determined using clonogenic assays and delayed tumor growth, inhibition of IL-6 by transfection of an IL-6 silencing vector increased radiosensitivity. Extensive DNA damage caused by radiation and anti-cancer agents can result in cell death or sensitivity to clinical treatment if left unrepaired [
36]. Phosphorylated H2AX is an indicator of double-strand breaks, and its expression after irradiation correlates with treatment sensitivity [
37]. Our data demonstrate that inhibition of IL-6 was associated with increased radiation-induced DNA damage and increased cell death. Moreover, the data from xenograft tumors demonstrated that inhibition of IL-6 attenuated angiogenesis and decreased p-STAT3 activation after irradiation. The expression of angiogenic factors is suggested to have predictive value for treatment response and outcome in patients with esophageal cancer [
38,
39]. Therefore, we suggest activation of STAT3 signaling and angiogenesis after irradiation was reported to be responsible for resistance to treatment and tumor regrowth after irradiation triggered by IL-6.
We further examined the predictive power of IL-6 for prognosis in esophageal SCC. Besides a lower response to treatment, enhanced expression of IL-6 was significantly associated with a higher clinical stage, a greater risk of distant metastasis and shorter survival. In a multivariate analysis, IL-6 retained predictive power for OS.
These findings indicate that IL-6-positive esophageal cancer provides a suitable microenvironment for the development of tumor growth and treatment resistance mediated by induction of angiogenesis, enhancement of cell mobility, and promotion of EMT. Our data support the emerging notion that IL-6 and p-STAT3 are clinically significant predictors, and suggest that IL-6 may represent a suitable target for esophageal SCC treatment.
Competing interests
The authors confirm that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.
Authors’ contributions
MFC conceived of the study, performed the study and coordination and assisted in editing of manuscript. PTC performed the study and drafted the manuscript. MSL conceived of the study and participated in its design and coordination. PYL helped in histology and IHC staining. WCC conceived part of the study and performed the statistical analysis. KDL participated in its design and coordination. All authors read and approved the final manuscript.